MEIP News and Press, MEI Pharma Inc. From 04/13/21

MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA) Topline TIDAL Study D...

MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021 Investor and Analyst Video Webcast Event ...

MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , April 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into MEI Pharma, Inc. (NasdaqGS: MEIP). From August 2017, the Company repeatedly touted the...

MEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models PR Newswire SAN DIEGO , March 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (...

MEI Pharma to present at the virtual H.C. Wainwright Global Life Sciences Conference 2021 PR Newswire SAN DIEGO , March 2, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer...

MEI PHARMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc. - MEIP MEI PHARMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates...

MEI Pharma (MEIP): Q2 GAAP EPS of -$0.16 beats by $0.01.Revenue of $9.17M (+807.9% Y/Y) beats by $5.78M.Shares -2% AH.Press Release For further details see: MEI Pharma EPS beats by $0.01, beats on revenue

MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights --Multiple Clinical Development Milestones Anticipated in 2021-- --MEI Maintains Strong Financial Position with $180 Million in Cash-- PR Newswire SAN DIEGO , Feb. 4, 2021...

MEI Pharma ([[MEIP]] +6.4%) has announced that the Phase 1b trial arm exploring zandelisib in combination with BeiGene's Brukinsa (zanubrutinib) has completed the safety evaluation stage in patients with B-cell malignancies and is expanding into disease specific B-cell malignancy cohorts.Anti...